Market Place
Sourcing Support
Nuvation Bio Appoints Philippe Sauvage As Chief Financial Officer
07 Oct 2024 //
BUSINESSWIRE
Nuvation Bio Reports Q2 2024 Results And Business Update
05 Aug 2024 //
BUSINESSWIRE
Nuvation Bio Updates On ROS1 Inhibitor Taletrectinib
23 Jul 2024 //
BUSINESSWIRE
Innovent`s Taletrectinib ROS1 Inhibitor Data Published, Presented At ASCO
02 Jun 2024 //
PR NEWSWIRE
Nuvation`s Taletrectinib ROS1 Inhibitor Data Published In JCO, At ASCO
01 Jun 2024 //
BUSINESSWIRE
Innovent`s Taletrectinib ROS1 Inhibitor Pivotal Data Published, At ASCO
01 Jun 2024 //
PR NEWSWIRE
Nuvation Presents Taletrectinib ROS1 Inhibitor Data at ASCO
24 Apr 2024 //
BUSINESSWIRE
Innovent and AnHeart Announce the NMPA Has Accepted NDA for Taletrectinib
05 Mar 2024 //
PR NEWSWIRE
AnHeart and Innovent Announce NMPA Has Granted Taletrectinib Priority Review
18 Dec 2023 //
BUSINESSWIRE
AnHeart Therapeutics and Foundation Medicine Announce Collaboration
14 Dec 2023 //
BUSINESSWIRE
AnHeart Announces Agreement With Nippon Kayaku for Taletrectinib in Japan
30 Oct 2023 //
BUSINESSWIRE
AnHeart Therapeutics’ Taletrectinib Shrank Tumors in More Than 90% of People
21 Oct 2023 //
BUSINESSWIRE
AnHeart & NewG Lab Receive Orphan Drug Designation for Taletrectinib
12 Sep 2022 //
BUSINESSWIRE
AnHeart Receives FDA Breakthrough Therapy Designation
03 Aug 2022 //
BUSINESSWIRE
AnHeart Therapeutics Appoints Dr. Shuanglian Li as Chief Medical Officer (US)
01 Aug 2022 //
BUSINESSWIRE
AnHeart & Innovent Present Updated PII Efficacy and Safety Data of Taletrectinib
06 Jun 2022 //
BUSINESSWIRE
AnHeart Therapeutics Announces First Patient Dosed in Global Phase 2 TRUST-II
25 Oct 2021 //
BUSINESSWIRE
First Patient Dosed in Phase II Basket Trial of Taletrectinib
18 Jun 2021 //
GLOBENEWSWIRE
First Patient Dosed in Phase II Basket Trial of Taletrectinib
17 Jun 2021 //
GLOBENEWSWIRE
AnHeart Announces Publication of Pooled Analysis of two Phase 1 Studies
29 Oct 2020 //
BIOSPACE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.